These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18483380)

  • 1. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
    Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
    Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
    Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE
    J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
    Bradley DP; Tessier JJ; Lacey T; Scott M; Jürgensmeier JM; Odedra R; Mills J; Kilburn L; Wedge SR
    Magn Reson Imaging; 2009 Apr; 27(3):377-84. PubMed ID: 18814988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
    Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
    Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
    Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
    Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
    Lindsay CR; MacPherson IR; Cassidy J
    Future Oncol; 2009 May; 5(4):421-32. PubMed ID: 19450171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
    Isobe T; Komatsu R; Honda M; Kuramoto S; Shindoh H; Tabo M
    J Toxicol Sci; 2014 Apr; 39(2):237-42. PubMed ID: 24646704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
    Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
    Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
    Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
    Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
    Siemann DW; Brazelle WD; Jürgensmeier JM
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):897-903. PubMed ID: 19215823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.